This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.

The day before the meeting ended was the busiest day at the meeting with re­gard to myeloma research.  It featured a session of oral pre­sen­ta­tions in the morn­ing and a poster session in the afternoon. In addi­tion, an education ses­sion was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treat­ment of mul­ti­ple myeloma (article in the ASCO 2014 Edu­ca­tional Book).

This update …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began yester­day morning in Chicago and will run through Tuesday.

Myeloma-related pre­sen­ta­tions were made during two sessions yes­ter­day.

One session was designed to better educate physicians about per­son­al­ized ther­apy for elderly patients with lymphoid malig­nan­cies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treat­ment options for older multiple myeloma patients.

The key myeloma-related re­search pre­sented yesterday was made public during a poster session in the afternoon about studies …

The year 2013 is likely to be remembered as a very good year when it comes to re­search related to multiple myeloma.

Previous years have witnessed re­search shedding new light on existing my­e­lo­ma ther­a­pies, as well as addi­tional re­search about poten­tial new ther­a­pies.

But, in the past, most of the im­por­tant new ther­a­pies that were being re­searched were from existing classes of ther­apy, making them less likely to offer dramatic im­prove­ments in the treat­ment of the dis­ease.

In 2013, not only was there more re­search about existing ther­a­pies, and more re­search about …

The 2013 annual meeting of the American Society of Hematology (ASH), which took place last month, featured many oral and poster presentations about Kyprolis, one of the newest drugs to be approved for the treat­ment of multiple myeloma.

The drug con­tinues to be tested in various com­bi­na­tions in both newly diag­nosed and re­lapsed/refractory multiple myeloma patients, as well as in patients with the myeloma precursor disease smol­der­ing myeloma.

In most trials, Kyprolis (car­filz­o­mib) was com­bined with dex­a­meth­a­sone (Decadron) and a third drug, some­times even a fourth drug, such as …

Results from three clinical trials involving the inves­ti­ga­tional drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.

The trials evaluated the efficacy of filanesib (ARRY-520) alone and in com­bi­na­tion with other agents as potential treat­ments for re­lapsed and refractory multiple myeloma patients.

Overall, the trial results presented at ASH con­firm existing impressions of filanesib as a promising potential myeloma ther­apy.

Results of a Phase 2 trial of filanesib with or without low-dose dex­a­meth­a­sone (Decadron) show that 16 per­cent of patients who …

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treat­ment options for newly diag­nosed, re­lapsed and refractory, and older patients.

This ASH update highlights most of the oral …

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.

The myeloma study included in this session was …